New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.
News|Articles|September 22, 2026
- September 2026
- Volume 92
- Issue 9
Multilevel Anticoagulant Stewardship Enhances Patient Safety
Fact checked by: Afton Woodward
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
Advertisement
Advertisement
Each year, anticoagulants such as apixaban (Eliquis; Bristol Myers Squibb, Pfizer) and rivaroxaban (Xarelto; Johnson & Johnson) account for 5 of every 1000 emergency department visits attributed to medication adverse effects in adults 65 years and older. Among adults aged 45 to 64 years, they account for 1 of every 1000 visits—a rate comparable to that associated with prescription opioids.1
Related to this article
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Advertisement
Advertisement